Dexcom number of employees

Dexcom reported 11,100 employees at December 31, 2025 in its latest annual report, up 800 (7.8%) on the year before. That compares with 6,300 at December 31, 2021. Revenue per employee was $420,000.

Headcount by year

Fiscal year end	Employees	Change	Revenue per employee	Source
December 31, 2025	11,100	+800 (7.8%)	$420,000	10-K, filed February 12, 2026
December 31, 2024	10,300	+700 (7.3%)	$391,553	10-K, filed February 18, 2025
December 31, 2023	9,600	+2,000 (26.3%)	$377,323	10-K, filed February 8, 2024
December 31, 2022	7,600	+1,300 (20.6%)	$382,868	10-K, filed February 9, 2023
December 31, 2021	6,300	—	$388,651	10-K, filed February 14, 2022

What the annual reports say

As of December 31, 2025, we have approximately 11,100 employees around the globe, including 11,000 full-time employees. 2025 annual report
As of December 31, 2024, we have approximately 10,300 employees around the globe, including 10,200 full-time employees. 2024 annual report
As of December 31, 2023, we have approximately 9,600 employees around the globe, including 9,500 full-time employees. 2023 annual report
As of December 31, 2022, we have approximately 7,600 employees around the globe, including 7,500 full-time employees. 2022 annual report
Human Capital As of December 31, 2021, we have approximately 6,300 full-time employees and approximately 700 contract and temporary employees around the globe. 2021 annual report

Headcount as the company states it in Item 1 of its annual report (some count full-time equivalents or exclude part-time and temporary staff), at the date it gives. Years where the report states no clear total are left out rather than estimated. Changes can reflect acquisitions and disposals as well as hiring and job cuts.

Compare with peers

Head to head: DXCM vs IDXX DXCM vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Dexcom's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dexcom.